2-氯-3-甲基喹啉 | 57876-69-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-氯-3-甲基喹啉
• 中文别名: 甲霜灵
• 英文名称: 2-chloro-3-methyl-quinoline
• 英文别名: 3-methyl-2-chloroquinoline；2-Chlor-3-methyl-chinolin；2-Chloro-3-methylquinoline
• CAS: 57876-69-4
• 化学式: C₁₀H₈ClN
• mdl: MFCD00100265
• 分子量: 177.633
• InChiKey: UMYPPRQNLXTIEQ-UHFFFAOYSA-N

物化性质

• 熔点：
  83-84 °C
• 沸点：
  292.84°C (rough estimate)
• 密度：
  1.1810 (rough estimate)
• 稳定性/保质期：
  避免接触氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933499090
• 安全说明：
  S24/25
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  在密封的储藏器中存放，并置于阴凉、干燥处。

SDS

Name:	2-Chloro-3-Methylquinoline 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	57876-69-4

Section 1 - Chemical Product MSDS Name:2-Chloro-3-Methylquinoline 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
57876-69-4	2-Chloro-3-Methylquinoline	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 57876-69-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 82.00 - 84.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H8ClN
Molecular Weight: 177.63

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 57876-69-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Chloro-3-Methylquinoline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 57876-69-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 57876-69-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 57876-69-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-3-甲基喹啉 在 叔丁基过氧化氢 、 sodium tetrahydroborate 、 N-溴代丁二酰亚胺(NBS) 、 selenium(IV) oxide 、 cerium(III) chloride 、 硫酸 、 potassium tert-butylate 、 sodium acetate 、 silica gel 、 溶剂黄146 、 过氧化苯甲酰 作用下， 以 四氢呋喃 、 四氯化碳 、 乙二醇二甲醚 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， -78.0~140.0 ℃ 、10.64 MPa 条件下， 反应 17.83h， 生成 喜树碱
  参考文献：
  名称：

  Ciufolini, Marco A.; Roschangar, Frank, Angewandte Chemie, 1996, vol. 108, # 15, p. 1789 - 1791

  摘要：

  DOI：
• 作为产物：
  描述：

  3-甲基喹啉N-氧化物 在 三氯乙腈 、 三苯基膦 作用下， 以 甲苯 为溶剂， 反应 4.0h， 以61%的产率得到2-氯-3-甲基喹啉
  参考文献：
  名称：

  使用 PPh3/Cl3CCN 区域选择性氯化喹啉 N-氧化物和异喹啉 N-氧化物

  摘要：

  已经开发了一种用于杂环 N-氧化物的区域选择性 C2-氯化的新方法。以PPh3/Cl3CCN为氯化试剂，以令人满意的收率顺利地获得了所需的N-杂环氯化物。反应以高效和选择性的方式在广泛的底物上进行，表现出优异的官能团耐受性。此外，该氯化反应可用于修饰有吸引力的配体和药物的 N-杂环支架。

  DOI：

  10.1002/ejoc.201501567

文献信息

• Process for preparation of benzo[f]quinolinones
  申请人：Eli Lilly and Company

  公开号：US05578724A1

  公开（公告）日：1996-11-26

  A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase and their preparation is disclosed.

  一系列苯醌啉-3-酮类药物在治疗由I型和II型5α-还原酶引起的疾病方面具有有效性，并且其制备方法已被披露。
• Practical total synthesis of (+)-Camptothecin: The full story
  作者：Marco A. Ciufolini、Frank Roschangar

  DOI：10.1016/s0040-4020(97)00365-7

  日期：1997.8

  The evolution of our strategy for the synthesis of (+)-Camptothecin and related substances is presented in detail.

  详细介绍了我们合成（+）-喜树碱和相关物质的策略的演变。
• Pyrimidine Derivatives As HSP90 Inhibitors
  申请人：Chessari Gianni

  公开号：US20090215777A1

  公开（公告）日：2009-08-27

  The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR 3 ; R 1 is a monocyclic or bicyclic carbocyclic or heterocyclic ring of 5 to 10 ring members of which up to two ring members may be heteroatoms selected from N, O and S and the remainder are carbon atoms, the carbocyclic or heterocyclic ring being optionally substituted by one or more substituent groups independently selected from R 10 ; and R 2 , R 3 and R 10 are as defined in the claims.

  该发明提供了一种化合物，用作Hsp90的抑制剂，该化合物具有以下式（I）：或其盐、互变异构体、溶剂合物或N-氧化物；其中：A为N或CR基团；R1为由5至10个环成员组成的单环或双环碳环或杂环，其中最多两个环成员可以是从N、O和S中选择的杂原子，其余为碳原子，碳环或杂环可以选择地被一个或多个取代基独立地选择自R10的取代基取代；而R2、R3和R10如权利要求中所定义。
• [EN] 4-FLUOROPIPERIDINE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE DE TYPE COMPOSÉS DE 4-FLUOROPIPÉRIDINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014113303A1

  公开（公告）日：2014-07-24

  The present invention is directed to 4-fluoropiperidine compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及4-氟哌啶化合物，它们是促进睡眠的受体拮抗剂，可用于治疗或预防涉及促进睡眠的神经和精神障碍和疾病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及促进睡眠的这类疾病中使用这些化合物和组合物。
• Method of preventing prostatic cancer development
  申请人：ELi Lilly and Company

  公开号：US05629007A1

  公开（公告）日：1997-05-13

  A series of benzoquinolin-3-ones are pharmaceuticals effective in preventing the development of prostatic cancer, or preventing or treating the metastasis to bone of prostatic cancer.

  一系列苯醌啉-3-酮类药物在预防前列腺癌的发展，或预防或治疗前列腺癌转移到骨骼方面具有有效作用。